Compare · ARGX vs TARS
ARGX vs TARS
Side-by-side comparison of argenx SE (ARGX) and Tarsus Pharmaceuticals Inc. (TARS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and TARS operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $52.52B, about 15.0x TARS ($3.50B).
- Both names hit the wire about 6 times in the past 4 weeks.
- ARGX has more recent analyst coverage (25 ratings vs 15 for TARS).
- Company
- argenx SE
- Tarsus Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $52.52B
- $3.50B
- 1M return
- -17.73%
- -
- 1Y return
- -2.77%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2020
- News (4w)
- 6
- 6
- Recent ratings
- 25
- 15
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Latest ARGX
- argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
- SEC Form 6-K filed by argenx SE
- argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
- argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
- SEC Form 6-K filed by argenx SE
- argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
- argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE
Latest TARS
- Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
- SEC Form S-3ASR filed by Tarsus Pharmaceuticals Inc.
- SEC Form S-3ASR filed by Tarsus Pharmaceuticals Inc.
- Amendment: SEC Form 8-K/A filed by Tarsus Pharmaceuticals Inc.
- Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
- Goldman resumed coverage on Tarsus Pharmaceuticals with a new price target
- Director Pyott David E I converted options into 201 shares (SEC Form 4)
- Director Link William J Phd converted options into 201 shares and sold $979,744 worth of shares (12,500 units at $78.38) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 94,487 units (SEC Form 4)
- Director Yarno Wendy L converted options into 302 shares, increasing direct ownership by 2% to 16,956 units (SEC Form 4)
- Barclays resumed coverage on Tarsus Pharmaceuticals with a new price target